Swiss National Bank Acquires Shares of 203,100 Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Swiss National Bank purchased a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) in the fourth quarter, HoldingsChannel reports. The firm purchased 203,100 shares of the company’s stock, valued at approximately $1,218,000.

Other institutional investors have also recently bought and sold shares of the company. KBC Group NV acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at $50,000. Townsquare Capital LLC acquired a new stake in Adaptive Biotechnologies in the third quarter worth about $56,000. GAMMA Investing LLC bought a new stake in Adaptive Biotechnologies during the 4th quarter worth about $59,000. Centiva Capital LP acquired a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $80,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $93,000. Institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ADPT. The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies from a “neutral” rating to a “buy” rating and increased their price objective for the company from $8.00 to $9.00 in a report on Friday, March 21st. BTIG Research increased their price target on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Scotiabank lifted their price objective on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 13th. Finally, Piper Sandler restated an “overweight” rating and set a $11.00 target price (up previously from $7.00) on shares of Adaptive Biotechnologies in a report on Thursday, February 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $9.40.

Insider Activity at Adaptive Biotechnologies

In related news, insider Francis Lo sold 20,875 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $6.99, for a total transaction of $145,916.25. Following the sale, the insider now directly owns 332,846 shares in the company, valued at $2,326,593.54. This trade represents a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Chad M. Robins sold 211,160 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the completion of the transaction, the chief executive officer now directly owns 2,576,701 shares of the company’s stock, valued at approximately $21,901,958.50. The trade was a 7.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 757,601 shares of company stock worth $6,040,624. 6.20% of the stock is owned by company insiders.

Adaptive Biotechnologies Stock Down 6.7 %

Shares of NASDAQ ADPT opened at $7.67 on Friday. Adaptive Biotechnologies Co. has a twelve month low of $2.28 and a twelve month high of $9.01. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -7.04 and a beta of 1.53. The company’s fifty day moving average is $7.89 and its 200-day moving average is $6.37.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. During the same quarter last year, the firm earned ($0.30) EPS. On average, research analysts anticipate that Adaptive Biotechnologies Co. will post -0.92 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.